BioMarin Pharmaceutical | BMRN - Ebitda


BioMarin Pharmaceutical reported $-5.26M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Bayer EUR 1.51B 1.28B Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -5.26M 300.71M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
Insmed USD -314.19M 31.48M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Moderna USD -790M 582M Dec/2025
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 5.66B 3.77B Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
United Therapeutics USD 436.8M 34.2M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025